SEC Form 4 · accession 0001193125-26-271344
Parabilis Medicines, Inc. · PBLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward M Fitzgerald
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 15, 2026 · 5:35 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001657677
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | C | 5,539 | — | A | 5,539 | D | |
| Common StockF2 | Jun 11, 2026 | C | 3,878 | — | A | 9,417 | D | |
| Common StockF3 | Jun 11, 2026 | C | 5,271 | — | A | 14,688 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF1 | — | Jun 11, 2026 | C | 5,332 | A | — | — | Common Stock | 5,539 | 0 | D |
| Series C Preferred StockF2 | — | Jun 11, 2026 | C | 3,666 | A | — | — | Common Stock | 3,878 | 0 | D |
| Series F Preferred StockF3 | — | Jun 11, 2026 | C | 8,111 | A | — | — | Common Stock | 5,271 | 0 | D |
Explanation of responses
- F1Each share of Series B Preferred Stock was convertible into Common Stock on a 1 to 1.0389 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series B Preferred Stock had no expiration date.
- F2Each share of Series C Preferred Stock was convertible into Common Stock on a 1 to 1.0578 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series C Preferred Stock had no expiration date.
- F3Each share of Series F Preferred Stock was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Series F Preferred Stock had no expiration date.